Investor presentation
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Investor presentation
Hardman & Co Life Sciences Investor Forum
London, UK, 21 September, 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces Greg Madison, CEO of Shield, will be presenting at the Hardman & Co Life Sciences Investor Forum on Thursday 23 September 2021.
The webinar event will begin at 17:00 (BST) and investors can register to attend here: https://hardman-co.com/p/49CL-HU2/join-our-webinar
No new material information will be disclosed at this event and the presentation will be made available on the Company website shortly after the event.
For further information please contact:
|
Shield Therapeutics plc |
|
|
Greg Madison, CEO |
+44 (0) 191 511 8500 |
|
Hans-Peter Rudolf, CFO |
|
|
Nominated Adviser and Joint Broker |
|
|
Peel Hunt LLP |
|
|
James Steel/Christopher Golden |
+44 (0)20 7418 8900 |
|
Joint Broker finnCap Ltd Geoff Nash/Alice Lane/George Dollemore |
+44 (0)20 7220 0500 |
|
|
|
|
Financial PR & IR Advisor |
|
|
Walbrook PR |
+44 (0)20 7933 8780 or shield@walbrookpr.com |
|
Paul McManus/Lianne Cawthorne |
|
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. Accrufer® has been launched in the US in July 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
COMPANIES COVERED:
Latest directors dealings
- 2 hours ago Bango
- 2 hours ago IntegraFin Holding
- 3 hours ago Worsley Investors Limited NPV
- 4 hours ago Coca-Cola Europacific Partners (DI)
- 4 hours ago easyJet